OpRegen
Geographic Atrophy secondary to Age-related Macular Degeneration
Phase 1/2aActive (Partnered with Genentech)
Key Facts
Indication
Geographic Atrophy secondary to Age-related Macular Degeneration
Phase
Phase 1/2a
Status
Active (Partnered with Genentech)
Company
About Lineage Cell Therapeutics
Lineage Cell Therapeutics is a clinical-stage biotech focused on developing novel, allogeneic cell therapies for unmet medical needs in neurology, oncology, and ophthalmology. Its core strategy is built on the proprietary AlloSCOPE™ platform, which enables the directed differentiation of pluripotent cells into scalable, 'off-the-shelf' therapeutic products. Recent achievements include a significant collaboration with Genentech for retinal programs and advancing its lead candidate, OPC1, for spinal cord injury. The company aims to validate its platform through clinical milestones and strategic partnerships to address large, underserved markets.
View full company profileTherapeutic Areas
Other Geographic Atrophy secondary to Age-related Macular Degeneration Drugs
| Drug | Company | Phase |
|---|---|---|
| Gildeuretinol (ALK-001) | Alkeus Pharmaceuticals | Phase 2/3 |